Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Docetaxel clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Docetaxel as a study intervention. Browse Docetaxel recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 10:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1320
Shown on this page
12
Current sort
Recently updated
Therapy scope
Docetaxel
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Docetaxel. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 301–312 of 1,320 matching trials for Docetaxel.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 1 Interventional Results available

BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

NCT02204072
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
BI 836845, Enzalutamide
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
3
States / cities
Detroit, Michigan • New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 26, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

NCT01275677
View directory record Official record
Conditions
HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Cyclophosphamide, Docetaxel, Doxorubicin, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Trastuzumab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
3,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1259
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 797 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 26, 2026, 10:55 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

NCT04721015
View directory record Official record
Conditions
Advanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC)
Interventions
ABBV-637, Docetaxel, Osimertinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Boston, Massachusetts • St Louis, Missouri • Huntersville, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 26, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Results available

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

NCT03884556
View directory record Official record
Conditions
Solid Tumor, Lymphoma
Interventions
TTX-030, Pembrolizumab, Gemcitabine, nab paclitaxel
Drug
Lead sponsor
Trishula Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Orange, California • Sacramento, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 26, 2026, 10:55 AM EDT
Completed Phase 2 Interventional Results available

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

NCT03739710
View directory record Official record
Conditions
Neoplasms
Interventions
Docetaxel, Feladilimab, Ipilimumab, GSK4428859A, Dostarlimab, GSK6097608
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Los Angeles, California • St Louis, Missouri • The Bronx, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 26, 2026, 10:55 AM EDT
Completed Phase 1 Interventional

A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors

NCT05625412
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BMS-986360, Docetaxel, Nivolumab, Capecitabine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Los Angeles, California • New Orleans, Louisiana • Hackensack, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 26, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

NCT04100018
View directory record Official record
Conditions
Prostate Cancer
Interventions
Nivolumab, Prednisone, Docetaxel, Placebo
Biological · Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
45
States / cities
Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 26, 2026, 10:55 AM EDT
Terminated Phase 2 Interventional Results available

A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

NCT05169684
View directory record Official record
Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
BMS-986218, Docetaxel, Nivolumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
25
States / cities
Tucson, Arizona • Los Angeles, California • Littleton, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 26, 2026, 10:55 AM EDT
Terminated Phase 2 Interventional Results available

Study of Magrolimab in Patients With Solid Tumors

NCT04827576
View directory record Official record
Conditions
Solid Tumor
Interventions
Magrolimab, Docetaxel
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
21
States / cities
Goodyear, Arizona • La Jolla, California • Santa Monica, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 26, 2026, 10:55 AM EDT
Completed Phase 1 Interventional

Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

NCT00405405
View directory record Official record
Conditions
Head and Neck Cancer, Parotid Gland Cancer, Thyroid Gland Cancer, Melanoma, Stage IV Head and Neck Cancer
Interventions
Cisplatin, Docetaxel, Bevacizumab, Erlotinib, Radiotherapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 26, 2026, 10:55 AM EDT
Terminated Phase 2 Interventional Results available

Induction Chemo-Nivo in Unresectable Stage III NSCLC

NCT06003075
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell, Lung Cancer Stage III
Interventions
Nivolumab and Chemotherapy, Nivolumab, Post Induction Surgery, Post Induction XRT
Combination Product · Drug · Procedure + 1 more
Lead sponsor
Ralph G Zinner
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 26, 2026, 10:55 AM EDT
Active, not recruiting Phase 2 Interventional

REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

NCT03951831
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
REGN2810, Degarelix, Leuprolide Acetate, Docetaxel
Drug
Lead sponsor
Mark Stein
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 26, 2026, 10:55 AM EDT

About this Docetaxel clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Docetaxel as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Docetaxel.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Docetaxel.